Effects of anti-fibrillarin antibodies on building of functional nucleoli at the end of mitosis.
During mitosis some nuclear complexes are relocalized at the chromosome periphery and are then reintegrated into the re-forming nuclei in late telophase. To address questions concerning translocation from the chromosome periphery to nuclei, the dynamics of one nucleolar perichromosomal protein which is involved in the ribosomal RNA processing machinery, fibrillarin, was followed. In the same cells, the onset of the RNA polymerase I (RNA pol I) activity and translocation of fibrillarin were simultaneously investigated. In PtK1 cells, RNA pol I transcription was first detected at anaphase B. At the same mitotic stage, fibrillarin formed foci of increasing size around the chromosomes, these foci then gathered into prenucleolar bodies (PNBs) and later PNBs were targeted into the newly formed nucleoli. Electron microscopy studies enabled the visualization of the PNBs forming the dense fibrillar component (DFC) of new nucleoli. Anti-fibrillarin antibodies microinjected at different periods of mitosis blocked fibrillarin translocation at different steps, i.e. the formation of large foci, foci gathering in PNBs or PNB targeting into nucleoli, and thereby modified the ultrastructural organization of the nucleoli as well as of the PNBs. In addition, antibody-bound fibrillarin seemed localized with blocks of condensed chromatin in early G1 nuclei. It has been found that blocking fibrillarin translocation reduced or inhibited RNA pol I transcription. It is postulated that when translocation of proteins belonging to the processing machinery is inhibited or diminished, a negative feed-back effect is induced on nucleolar reassembly and transcriptional activity.
Fomproix
N
N
Institut Jacques Monod, Paris, France.
Gébrane-Younès
J
J
Hernandez-Verdun
D
D
D000818:Animals; D001323:Autoantibodies / Q000378:metabolism* / Q000494:pharmacology; D001324:Autoantigens / Q000378:metabolism*; D002460:Cell Line; D002466:Cell Nucleolus / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D002467:Cell Nucleus / Q000187:drug effects / Q000502:physiology; D002868:Chromosomal Proteins, Non-Histone / Q000378:metabolism*; D004275:DNA, Ribosomal; D006367:HeLa Cells; D006801:Humans; D007700:Kinetics; D008394:Marsupialia; D008845:Microinjections; D008938:Mitosis / Q000187:drug effects / Q000502:physiology*; D009697:Nucleolus Organizer Region / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D012261:Ribonucleoproteins / Q000378:metabolism*; D014158:Transcription, Genetic
D001323:Autoantibodies; D001324:Autoantigens; D002868:Chromosomal Proteins, Non-Histone; D004275:DNA, Ribosomal; D012261:Ribonucleoproteins; C047458:fibrillarin